RGRX stock forecast
Our latest prediction for RegeneRx Biopharmaceuticals, Inc.'s stock price was made on the May 13, 2019 when the stock price was at 0.20$.
In the short term (2weeks), RGRX's stock price should outperform the market by 5.62%. During that period the price should oscillate between -11.39% and +21.26%.
In the medium term (3months), RGRX's stock price should outperform the market by 7.91%. During that period the price should oscillate between -25.34% and +58.47%.Get email alerts
Create a solid portfolio with RGRX
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc. focuses on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. Its products include RGN-259, RGN-352, and RGN-137. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.02$ per share.
The book value per share is -0.02$
Three months stock forecastMay 13, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|